Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 7/20 | 0.42 |
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447637 | 0.83 | CRBN (0.47) | CRBNDDB1SCN9AADAMTS5MMP2 | |
| SCHEMBL2917541 | 0.81 | IDO1 (0.40) | CRBNDDB1IDO1TDO2 | |
| SCHEMBL2916637 | 0.80 | IDO1 (0.39) | IDO1TDO2 | |
| SCHEMBL2917240 | 0.79 | GPR119 (0.42) | — | |
| SCHEMBL14117695 | 0.74 | SCN9A (0.61) | CRBNDDB1SCN9AADAMTS5MMP13 | |
| SCHEMBL14117685 | 0.74 | CRBN (0.56) | CRBNDDB1SCN9AADAMTS5MMP2 | |
| SCHEMBL14117661 | 0.70 | CRBN (0.60) | CRBNDDB1SCN9AADAMTS5MMP2 | |
| SCHEMBL15727931 | 0.70 | GPR119 (0.53) | — | |
| SCHEMBL1632532 | 0.69 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL23643942 | 0.68 | GPR119 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | CRBN 2600/4885DDB1 1599/4885SCN9A 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.